Developer · United States

AegisCN LLC

Privately held Durham, North Carolina biotech founded in 2012 to develop apolipoprotein E (apoE) mimetic peptides for acute brain injury and neuroinflammation. Its sole clinical asset is CN-105, licensed from Duke University, where co-inventor Daniel T. Laskowitz is a neurologist and an AegisCN officer and equity holder. Duke University holds equity and an intellectual-property stake in CN-105.

1compound
2programs
2indications
Phase 2lead asset

Phase distribution

  • Phase 22

Modality

  • Peptide 1

Mechanism focus

Pipeline (1)

Catalysts · 1 upcoming · 5 reported

  • Mid-2024Delayed

    CN-105forIntracerebral hemorrhageTopline data

    CN-CATCH, the 240-patient Chinese dose-finding Phase 2, listed an estimated primary completion of May 2024 but has produced no results and its registry record has not been updated since February 2024.

    NCT06255977source ↗

Recently reported

  • 2026-06-23missed

    CN-105forIntracerebral hemorrhageFull results

    S-CATCH: the randomized Phase 2b in 60 Singaporean ICH patients confirmed safety but missed on 90-day functional outcome (mRS <=3 77.8% vs 66.7%, p=0.35).

    source ↗

  • 2026-04-01missed

    CN-105forPostoperative deliriumFull results

    MARBLE: CN-105 was safe and feasible but did not significantly reduce postoperative delirium (19.3% vs 26.5%, OR 0.66, p=0.29) or CSF cytokines in 186 randomized older surgical patients.

    source ↗

  • 2024-09-04met

    CN-105forPostoperative deliriumRegistry results

    MARBLE tabular results posted to ClinicalTrials.gov: median Grade II+ adverse events per patient 1 (CN-105, n=137) versus 2 (placebo, n=49), p=0.025.

    source ↗

  • 2022-02-01met

    CN-105forIntracerebral hemorrhageFull results

    CATCH: the open-label Phase 2a in 38 ICH patients met its safety primary with no excess hematoma expansion, and showed a 30-day mRS odds ratio of 2.69 (1.31-5.51) against matched historical controls.

    source ↗

  • 2017-06-01met

    CN-105forIntracerebral hemorrhageFull results

    Phase 1 in 48 healthy adults: no significant safety issues on single or repeated IV dosing, linear PK with ~3.6 h half-life and no accumulation.

    source ↗

Recent activity

  • Jun 23, 2026ReadoutCN-105·Intracerebral hemorrhagemissedS-CATCH: the randomized Phase 2b in 60 Singaporean ICH patients confirmed safety but missed on 90-day functional outcome (mRS <=3 77.8% vs 66.7%, p=0.35).source ↗
  • Apr 3, 2026Phase changeCN-105·Postoperative deliriumPhase 2Published in JAMA Network Open more than three years after completion: safe and feasible, but the reduction in postoperative delirium was not statistically significant (19.3% vs 26.5%, OR 0.66, p=0.29) and no CSF cytokine endpoint moved. The authors argue a Phase 3 is warranted; none has been registered.source ↗
  • Apr 1, 2026ReadoutCN-105·Postoperative deliriummissedMARBLE: CN-105 was safe and feasible but did not significantly reduce postoperative delirium (19.3% vs 26.5%, OR 0.66, p=0.29) or CSF cytokines in 186 randomized older surgical patients.source ↗
  • Sep 4, 2024ReadoutCN-105·Postoperative deliriummetMARBLE tabular results posted to ClinicalTrials.gov: median Grade II+ adverse events per patient 1 (CN-105, n=137) versus 2 (placebo, n=49), p=0.025.source ↗
  • Dec 28, 2022Phase changeCN-105·Postoperative deliriumPhase 2MARBLE completes enrolment and follow-up; 203 enrolled, 186 randomized 3:1 to CN-105 versus placebo.source ↗
  • Aug 24, 2022Phase changeCN-105·Intracerebral hemorrhagePhase 2China Phase 2 starts: 240-patient, 4-arm (placebo, 0.1, 0.3, 1.0 mg/kg) placebo-controlled dose-finding trial at Beijing Tiantan Hospital with SDM Bio Service Inc. Last registry update 2024-02-13; ClinicalTrials.gov status is now UNKNOWN and the estimated 2024-08 completion has passed with no results or publication.source ↗
  • Jun 16, 2022Phase changeCN-105·Intracerebral hemorrhagePhase 2S-CATCH completes with 60 randomized (30 CN-105 / 30 placebo). This is the last patient-facing activity in the ICH program to date.source ↗
  • Feb 1, 2022ReadoutCN-105·Intracerebral hemorrhagemetCATCH: the open-label Phase 2a in 38 ICH patients met its safety primary with no excess hematoma expansion, and showed a 30-day mRS odds ratio of 2.69 (1.31-5.51) against matched historical controls.source ↗
  • Jan 25, 2020Phase changeCN-105·Intracerebral hemorrhagePhase 2CATCH completes (38 enrolled). Published Neurocrit Care 2022: safe, no hematoma expansion, OR 2.69 (1.31-5.51) for lower 30-day mRS versus matched historical controls — an uncontrolled comparison.source ↗
  • Mar 24, 2019Phase changeCN-105·Intracerebral hemorrhagePhase 2S-CATCH opens in Singapore — the first randomized, double-blind, placebo-controlled test of CN-105 in ICH (NCT03711903; National Neuroscience Institute lead sponsor, AegisCN collaborator).source ↗
  • Jul 15, 2018Phase changeCN-105·Postoperative deliriumPhase 2MARBLE opens at Duke (NCT03802396). ClinicalTrials.gov study start 2018-07-15; the first patient was randomized 2019-04-17 per the publication.source ↗
  • Aug 28, 2017Phase changeCN-105·Intracerebral hemorrhagePhase 2Phase 2 entry: CATCH, an open-label multisite US proof-of-concept in acute primary supratentorial ICH, opens (NCT03168581; AegisCN lead sponsor, with Duke Clinical Research Institute and PharPoint Research).source ↗